Full Generic Medicine Info
Dosage/Direction for Use

Ocular hypertension, Open-angle glaucoma
Adult: As 1% susp: Instill 1 drop 2-3 times daily, either alone or as adjunctive therapy w/ a topical β-blocker or prostaglandin analogue.
Elderly: No dosage adjustment necessary.
Hypersensitivity to brinzolamide, sulfonamides. Hyperchloraemic acidosis.
Special Precautions
Patient w/ low endothelial cell count. Hepatic and severe renal (CrCl <30 mL/min) impairment. Pregnancy and lactation. Patient Counselling This drug may cause temporary blurred vision or other visual disturbances, if affected do not drive or operate machinery. Monitoring Parameters Monitor intraocular pressure.
Adverse Reactions
Blurred vision, taste abnormality (bitter, sour, or unusual taste), blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperaemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Drug Interactions
Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.
Brinzolamide is a carbonic anhydrase inhibitor that decreases secretion of aqueous humour thus reducing intraocular pressure.
Absorption: Absorbed into systemic circulation.
Distribution: Brinzolamide and metabolites: Accumulates in RBCs and bind to carbonic anhydrase. Plasma protein binding: Approx 60%.
Metabolism: Metabolised to N-desethyl brinzolamide.
Excretion: Via urine as unchanged drug and metabolites.
Ophthalmic: Store between 4-30°C.
ATC Classification
S01EC04 - brinzolamide ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.
Disclaimer: This information is independently developed by CIMS based on brinzolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in